Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MLN3126 in Healthy Subjects
NCT02209506Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MLN3126 in inflammatory bowel disease (IBD) (10 arms), sponsored by Takeda. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events at Day 22, Percentage of Participants Who Meet the Markedly Abnormal Criteria for Electrocardiogram Measurements at Day 22 and 2 more. Started Jul 2014; status: terminated.
02
Drugs
MLN3126
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02209506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209506.